Johnson & Johnson on Thursday said it will buy an 18.4% stake in Irish biotech company Elan, in a $1.5bn bid to crack the elusive but potentially lucrative market for Alzheimer’s disease treatments, reports the WSJ. The agreement gives J&J access to bapineuzumab, a closely watched experimental Alzheimer’s treatment.

This entry was posted by Gwen Robinson on Friday, July 3rd, 2009 at 5:11 and is filed under Capital markets. Tagged with Elan, Johnson & Johnson. Edit this entry.